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Summary
 
p53 has a key role in the negative regulation of cell proliferation, in the maintenance of ge-
nomic stability, and in the suppression of transformation and tumorigenesis. To identify novel
regulators of p53, we undertook two functional screens to isolate genes which bypassed either
p53-mediated growth arrest or apoptosis. In both screens, we isolated cDNAs encoding mac-
rophage migration inhibitory factor (MIF), a cytokine that was shown previously to exert both
local and systemic proinflammatory activities. Treatment with MIF overcame p53 activity in
three different biological assays, and suppressed its activity as a transcriptional activator. The
observation that a proinflammatory cytokine, MIF, is capable of functionally inactivating a tu-
mor suppressor, p53, may provide a link between inflammation and tumorigenesis.
Key words: macrophage migration inhibitory factor • p53 • inﬂammation and cancer • 
growth arrest • apoptosis
 
E
 
lucidating the molecular mechanisms of tumorigenesis
is essential for future progress in the diagnosis and treat-
ment of human cancer. Inactivation of tumor suppressor
genes is an essential step in the etiology of tumor initiation
and growth. A great deal of effort has focused on the role of
the p53 tumor suppressor in cancer (1, 2). Its pivotal posi-
tion is underscored by the observation that mutations in p53
are the most common genetic alteration in human tumors.
p53 has a key role in inducing growth arrest or apoptosis
after genotoxic stress (3–8). Cells lacking p53 are capable of
proliferation with damaged DNA, and thus are capable of
accumulating multiple, potentially oncogenic mutations (9,
10). In addition, p53 controls the onset of cellular senes-
cence, a process which limits the number of times a cell can
potentially divide and which may act as an antitumor
mechanism (11). Overcoming p53 function extends poten-
tial life span and directly contributes to cellular immortal-
ization (12–14).
In a variety of tumors, p53 is functionally inactivated,
but the gene remains intact (15–17). In these tumors, the
activity of p53 regulators may be altered. Thus, the identi-
fication and characterization of novel regulators of p53 ac-
tivity may have direct consequences for understanding the
etiology of multiple tumor types.
Eventual tumor formation has been associated with sev-
eral chronic inflammatory conditions, although the rela-
tionship between inflammation and tumor development
remains largely obscure at a molecular level (18, 19). Tu-
mor initiation is precipitated by a combination of onco-
genic mutational events and loss of the cellular controls that
prevent cell division in the presence of DNA damage, lead-
ing to fixation and propagation of these mutations (9). At
sites of inflammation, the release of reactive oxygen species
from activated phagocytes has been associated with geno-
toxic damage in adjacent cells (20, 21). However, it has
been unclear how these cells could bypass the normal con-
trols to prevent proliferation with damaged DNA.
Here, we have undertaken two functional screens to
identify negative regulators of p53 tumor suppressor activ-
ity. From each screen we isolated macrophage migration
inhibitory factor (MIF).
 
1
 
 Our observation that MIF, a
proinflammatory cytokine released at the sites of inflamma-
tion, is capable of functionally inactivating p53, a tumor
suppressor that normally functions to prevent proliferation
of cells carrying genotoxic damage, may provide a mecha-
nistic link between inflammation and cancer.
 
Materials and Methods
 
Construction of tet-GFP-p53 p53
 
2
 
/
 
2
 
 Mouse Embryonic Fibroblast
Cell Line.
 
p53
 
2
 
/
 
2
 
 mouse embryonic fibroblasts (MEFs; from T.
 
1
 
Abbreviations used in this paper:
 
 FBS, fetal bovine serum; GFP, green fluo-
rescent protein; GSNO, 
 
S
 
-nitrosoglutathione; MBP, maltose binding
 
protein; MEF, mouse embryonic fibroblast; MIF, macrophage migration
inhibitory factor; NO, nitric oxide; SNP, sodium nitroprusside. 
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Jacks, Massachusetts Institute of Technology, Cambridge, MA)
were sequentially infected with pWZL-Blast-rtta, a blasticidin se-
lectable retroviral vector expressing the reverse transactivator of
the tetracycline inducible system (22), and pBabe-puro-tet-GFP-
p53-sin, a self-inactivating retrovirus expressing a GFP-p53 fusion
protein under the control of the tetracycline inducible promoter.
Cells were drug selected, and a clone (TGP53-4) was isolated that
showed observable GFP-p53 expression, and growth arrest of the
cells after addition of 1 
 
m
 
g/ml doxycycline to the media.
 
Recombinant MIF.
 
EcoRI and SalI sites were introduced im-
mediately 5
 
9
 
 and 3
 
9
 
 to the open reading frame of human MIF by
PCR, and this EcoRI-SalI fragment was cloned into EcoRI-
XhoI sites of pMal-C2 (New England Biolabs). A maltose bind-
ing protein (MBP)–MIF fusion was expressed in BL21 
 
Escherichia
coli
 
 cells, affinity purified by amylose chromatography, and
cleaved using factor Xa. MBP was removed after cleavage by
amylose chromatography. Since MBP had no effect in any of the
assays used, some experiments were performed using rMIF im-
mediately after cleavage.
 
Bypass of p53-induced Growth Arrest.
 
TGP53-4 cells were in-
fected with a pHygroMarx I–derived provirus containing MIF
cDNA or empty vector control. After hygromycin selection,
cells were plated at 
 
z
 
5,000 cells/plate. 1 
 
m
 
g/ml doxycycline
was added to induce p53 expression in appropriate plates. Me-
dia were replaced every 3 d, containing fresh doxycycline
where necessary. After 10 d, cells were fixed in 1% glutaralde-
hyde and stained with 0.25% crystal violet. For experiments using
soluble rMIF, TGP53-4 cells were plated at 
 
z
 
10,000 cells/plate
in the presence or absence of 150 ng/ml of rMIF added to the
growth media. 24 h later, doxycycline was added to induce p53
expression. Media were replaced every 3 d containing fresh doxy-
cycline and/or rMIF. After 9 d, cells were fixed and stained as
above.
 
Elongation of Life Span of Primary Mouse Fibroblasts.
 
MEFs were
prepared from 14-d CD1 mouse embryos, and were repeatedly
passaged. Where necessary, cells were infected in passage 2 with
pMARXIV-p53
 
a
 
s, pWZLneo-MIF, or control viruses, and se-
lected by drug resistance for the selectable marker. One passage
before the onset of senescence (usually around passage 4–5), cells
were split and plated at 
 
z
 
300,000 cells/plate in the presence or
absence of rMIF. Fresh tissue culture media (containing rMIF
where appropriate) were replaced every 3 d. After 15–17 d, cells
were fixed in 1% glutaraldehyde and stained with crystal violet.
To determine cell concentration, crystal violet was resolubilized
in 10% acetic acid and absorbance at 595 nm was analyzed using a
Bio-Rad 550 microplate reader.
 
Apoptosis of Rat-1/mycER Cells.
 
Rat-1/mycER cells were
infected with retroviruses expressing LacZ, MIF, or Bcl2 cDNAs.
After drug selection, cells were plated onto acid-washed cover-
slips at low density and shifted to media containing 0.1% fetal bo-
vine serum (FBS) plus 0.1 
 
m
 
M estradiol to induce apoptosis. After
24 h, cells were stained with 4 mg/ml Hoechst 33342 for 10 min,
then washed and scored by fluorescent microscopy. Cells con-
taining condensed or fragmented DNA cells were scored as apop-
totic cells. At least 100 fields/slide were analyzed by two inde-
pendent observers.
 
Apoptosis of RAW264.7 Macrophages.
 
RAW264.7 macrophages
were pretreated with varying concentrations of MIF for 24 h, and
then treated with 0.25–1.0 mM sodium nitroprusside (SNP) or
0.5–1 mM 
 
S
 
-nitrosoglutathione (GSNO) for 8 h to 2 d. Cells
containing condensed or fragmented DNA after very brief fixing
with paraformaldehyde and staining with Hoechst 33258 were
scored as apoptotic cells.
 
Fluorescence Microscopy.
 
TGP53-4 cells were split onto cover-
slips in the presence or absence of 150 ng/ml MIF. 24 h later, 1
 
m
 
g/ml doxycycline was added to the media. 16 h after doxycy-
cline addition, cells were washed in PBS and fixed in 2%
paraformaldehyde, and GFP-p53 was visualized with a Zeiss Ax-
iophot fluorescent microscope using a standard FITC filter set.
 
Western Blots.
 
Cells were washed in PBS, harvested in PBS,
centrifuged, and lysed. Equal amounts of total protein (30–300 
 
m
 
g)
were heat-denatured, separated on a 10% SDS-polyacrylamide
gel, and blotted to nitrocellulose. Blots were probed with anti-
bodies that recognize p53 (DO-1, FL-393; Santa Cruz Biotech-
nology), MDM2 (SMP-14; Santa Cruz Biotechnology), Bax
(BAX 
 
D
 
p21; Santa Cruz Biotechnology), or p21 (23) followed by
a horseradish peroxidase–conjugated anti–mouse antibody, and
detected using enhanced chemiluminescence.
 
Northern Blots.
 
Total RNA was prepared from TGP53-4
cells after induction of GFP-p53. 10 
 
m
 
g was separated in a 1%
formaldehyde gel and blotted to Hybond-N
 
1
 
 membranes. Blots
were probed with random primed radiolabeled probes corre-
sponding to the full-length coding sequence of mouse p21 and
cyclin G. Radioactive signals were quantified using a Fuji FLA-
200 phospho/fluorescent imager, and normalized to loaded RNA
by quantification of fluorescence of ethidium bromide–stained ri-
bosomal RNA bands in the RNA gel, or after blotting to the
membrane.
 
Luciferase Assays.
 
TGP53-4 cells were cotransfected with
PG13, a plasmid which carries firefly luciferase under the control
of three tandem copies of a p53-responsive consensus sequence,
and pCDNA3-
 
b
 
-gal, a plasmid which carries 
 
b
 
-galactosidase
under the control of the CMV promoter. 1 d after transfection,
cells were split, pooled, and replated at 
 
z
 
500,000 cells/plate. 150
ng/ml rMIF was added to half of the plates. The next day, 1 
 
m
 
g/ml
doxycycline was added to the media to induce GFP-p53. At 0
and 10 h after induction, extracts were prepared, and luciferase
and 
 
b
 
-galactosidase activities were assayed using Promega kits.
Luciferase reporter activities were normalized to 
 
b
 
-galactosidase
expression levels.
 
Results
 
MIF Isolated in Screens for Negative Regulators of p53 Activity.
 
To identify novel regulators of p53 activity, we under-
took a screen to identify genes that, when expressed at high
level, were capable of bypassing p53-mediated growth ar-
rest. A p53
 
2
 
/
 
2
 
 MEF cell line was engineered to express a
GFP-p53 fusion protein under the control of a tetracycline
(doxycycline)-inducible promoter (22; TGP53-4 cell line).
GFP-p53 fusion proteins are localized normally and can
transactivate target genes (24; and data not shown). After
addition of doxycycline to the media, the p53 fusion pro-
tein was induced, and cells became growth arrested and
failed to form colonies.
We used the TGP53-4 cell line in a phenotype-based
screen to identify negative regulators of p53 activity.
These cells were infected with an A431 epidermoid carci-
noma–derived cDNA library in a Moloney murine leuke-
mia virus (MMLV)–based retroviral vector, pHygroMarx I
(25). pHygroMarx I contains a bacterial origin of replication,
zeocin resistance marker between the LTRs, and a loxP site
in the 3
 
9
 
 LTR, which is duplicated upon integration, to fa-
cilitate provirus recovery by Cre-mediated excision after in- 
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tegration into the genome. LinX (25) ecotropic retrovirus
producer cells were transiently transfected with this library,
and after 3 d, supernatant was used to infect TGP53-4 cells.
Approximately 4 
 
3
 
 10
 
6
 
 cells were infected. After drug selec-
tion for the library vector, cells were split at varying dilu-
tions, and 1 
 
m
 
g/ml doxycycline was added to the media to
induce expression of the GFP-p53 fusion protein. When nec-
essary, cells were split again to improve colony discrimination.
Cells that were no longer inhibited by p53 induction gave rise
to colonies in the presence of doxycycline. These clones were
infected with pBabe-puro-Cre, a Moloney murine leukemia
virus–based virus that strongly expresses Cre recombinase to
excise the provirus. Proviruses containing cDNAs from posi-
tive clones were recovered by Hirt extraction.
Proviruses were recovered from a total of 50 positive
colonies. Nucleotide sequencing and database analysis re-
vealed that cDNAs recovered from five different colonies
encoded the same protein, human MIF, a cytokine that
was shown previously to exert both local and systemic
proinflammatory activities (26). All cDNAs encoding MIF
were full length and in the sense orientation. The complete
upstream regions were sequenced from three of these re-
covered cDNAs. Two differed in the precise 5
 
9
 
 terminus,
indicating that they were derived from independent clones.
A cDNA-encoding MIF was also independently isolated
in a similar phenotype-based screen to identify negative
regulators of myc-dependent apoptosis in rat fibroblasts.
Rat-1 fibroblasts expressing a c-myc–estrogen receptor fu-
sion protein (Rat-1/mycER) were infected with pools of a
cDNA library prepared from Rat-1/mycER cells commit-
ted to apoptosis in pHygroMarx II. After drug selection,
cells were induced to undergo apoptosis by shifting to low
serum media (DMEM 
 
1
 
 0.1% FBS) plus 0.1 
 
m
 
M estradiol
(to induce c-myc activity) for 3 d, followed by 2 d of serum
starvation without estradiol. Cells that were protected from
apoptosis were recovered in media containing 10% FBS.
Rescued cells were subjected to three additional cycles of
apoptotic induction. Proviruses were recovered from apop-
tosis-resistant cells by Cre-mediated excision of genomic
DNA line (27). Since this screen was carried out in a cell
line expressing wild-type p53, and myc-driven apoptosis is
largely p53 dependent (28), inhibitors of p53 function were
expected to be recovered from this screen.
 
MIF Treatment Bypasses p53-mediated Growth Arrest.
 
To
confirm that MIF was capable of bypassing p53-mediated
growth arrest, a provirus containing MIF or a control provi-
rus was transduced into TGP53-4 cells. Doxycycline was
added to induce p53 expression. Numerous colonies formed
on plates containing MIF-expressing cells, but few or no col-
onies formed on plates containing control cells (Fig. 1 A).
Since MIF was originally identified as an extracellular
cytokine, we tested whether MIF protein could overcome
p53-mediated growth arrest upon addition as a recombi-
nant protein to the culture medium. MIF protein was pro-
duced as an MBP fusion protein, and cleaved to separate
MIF from MBP (Fig. 1 B). TGP53-4 cells were grown in
the presence or absence of recombinantly produced MIF
(rMIF) and doxycycline. Colony formation was observed
 
in the absence of doxycycline, or in the presence of doxy-
cycline, and rMIF, but not in the presence of doxycycline
alone. Therefore, MIF was capable of bypassing p53-medi-
ated growth arrest when added as a soluble factor (Fig. 1 C).
 
MIF Treatment Suppresses p53-dependent Transcriptional Ac-
tivation.
 
p53 might be inactivated by altering its subcellular
localization, by decreasing protein levels, or by suppressing
its ability to function as a transcriptional activator. Since
GFP-p53 can be visualized directly in cells and shows nor-
mal subcellular localization, we analyzed whether p53
showed altered subcellular localization in the presence of
MIF. No obvious difference in the subcellular localization
of GFP-p53 was observed; p53 showed nuclear localization
irrespective of MIF treatment (Fig. 2 A). p53 can also be
regulated by altering protein abundance; however, p53 pro-
tein levels were not reduced after MIF treatment (Fig. 2 B).
p53 primarily functions via its ability to transactivate
gene expression. Therefore, we tested whether MIF treat-
Figure 1. MIF treatment overcomes p53-induced growth arrest. (A)
Expression of MIF bypasses p53-induced growth arrest and allows colony
formation in a tetracycline-inducible GFP-p53 cell line. pH Mpv, Hy-
groMarx I-based provirus; HMpv-MIF, HygroMarx I-based provirus ex-
pressing human MIF; DOX, 1 mg/ml doxycycline. (B) Recombinantly
produced MBP-MIF before (lane 1) and after cleavage (lane 2). No con-
taminating bands were observed in Coomassie blue or Sypro orange–
stained gels. (C) Addition of 150 ng/ml soluble rMIF bypasses p53-
induced growth arrest of a tetracycline-inducible GFP-p53 cell line. 
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ment interfered with this activity. After induction of p53,
RNA was prepared from TGP53-4 cells grown in the pres-
ence or absence of MIF. The abundance of two p53 tran-
scriptional targets, p21 (29–31) and cyclin G (32), was as-
sessed by Northern blot (Fig. 2 B). Levels of p21 and cyclin
G in MIF-treated cells were decreased to 
 
z
 
50 and 40% of
control levels (Fig. 2 C). In addition, p53-dependent in-
duction of MDM2, another p53 target which acts in a
feedback loop to negatively regulate levels of p53 (33, 34)
was decreased in MIF-treated cells (Fig. 2 D).
The effect of MIF treatment on the activity of a p53-
dependent reporter was also assayed. TGP53-4 cells were
transfected with PG13-luc, a plasmid which carries firefly
luciferase under the control of tandem copies of a p53-
responsive consensus sequence (35), in the presence and
absence of MIF, and luciferase activity was assayed after in-
duction of GFP-p53. Treatment with rMIF suppressed
p53-dependent luciferase expression (Fig. 2 E). Considered
together, these data suggest that MIF treatment bypassed
p53-mediated growth arrest by suppressing p53-dependent
transcriptional activation.
 
MIF Treatment Suppresses p53-dependent Apoptosis.
 
In ad-
dition to its ability to induce growth arrest, p53 functions
to induce apoptosis in response to cellular stress in suscepti-
ble cells (5, 7, 8). As described above, we isolated a cDNA-
encoding MIF in a screen designed to identify inhibitors of
myc-dependent apoptosis, a process which is largely p53-
dependent. To formally confirm that MIF expression could
suppress this phenotype, Rat-1/mycER cells were infected
with an MIF-expressing virus and control viruses, and apop-
tosis was induced by serum starvation and estradiol treat-
ment. Cells that expressed MIF were partially protected
from apoptosis under these conditions, though not as effi-
ciently as cells that expressed Bcl2 (Fig. 3 A).
Since MIF regulates numerous functions of macrophages
in in vitro assays and in vivo, we also tested whether MIF
treatment was capable of inhibiting apoptosis in macrophages.
After activation, macrophages release nitric oxide (NO) as
part of their antimicrobial repertoire. However, high levels of
NO can, in turn, cause macrophage apoptosis. For example,
apoptosis is induced by treatment of RAW264.7 macro-
phages with cytokines that induce endogenous production of
NO, or with chemical releasers of NO. Apoptosis is associ-
ated with induction of p53 and is inhibited by expression of
antisense p53 constructs, indicating that NO-induced mac-
rophage apoptosis is p53 dependent (36, 37). To test whether
MIF treatment was capable of suppressing NO-induced apop-
tosis, we treated RAW264.7 macrophages with NO-releas-
Figure 2. MIF suppresses the transcriptional activity of p53. (A) Subcellular localization of
GFP-p53 in the presence or absence of MIF. GFP-p53 shows normal nuclear localization in
each case. (B and C) Levels of GFP-p53 protein, and p21 and cyclin G mRNA after induction
of GFP-p53 in the presence or absence of MIF. Data shown in C are averages from three inde-
pendent experiments. (D) Levels of GFP-p53 and MDM2 protein before or 10 h after induction
of GFP-p53 in the presence or absence of MIF. (E) p53-responsive luciferase reporter gene ex-
pression in the presence or absence of MIF after p53 induction. MIF treatment suppresses re-
porter gene expression. Data shown are averages from four independent experiments. 
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ers, SNP, or GSNO, in the presence of various concentra-
tions of rMIF. MIF treatment suppressed NO-induced
apoptosis in a dose-dependent manner (Fig. 3, B and C).
 
MIF Treatment Extends the Life Span of Primary Murine Fi-
broblasts.
 
p53 also plays a role in controlling the onset of
cellular senescence (12–14). Normal primary mouse fibro-
blasts are capable of a finite number of divisions in culture,
and ultimately arrest with a senescent morphology (11). Loss
of p53 allows primary mouse cells to extend their division
potential. Thus, in a colony formation assay, cells lacking
p53 are capable of forming colonies at passages at which
wild-type cells are not. Therefore, we tested whether MIF
was capable of elongating the potential life span of primary
MEFs. At one passage before the onset of senescence (pas-
sage 4–5), primary MEFs were plated in the presence or ab-
sence of rMIF. After 15 d, numerous colonies had formed
on plates treated with MIF, whereas none were observed in
the absence of MIF. This indicated that MIF treatment, like
loss of p53, was capable of inducing elongated life span (Fig.
4 A). Colony formation occurred at a frequency of 
 
z
 
10
 
2
 
4
 
colonies/cell (the frequency of colony formation observed
with cells expressing an antisense or dominant negative p53
under identical conditions is 2–3 
 
3
 
 10
 
2
 
4
 
 and 1–3 
 
3
 
 10
 
2
 
3
 
with fibroblasts prepared from a p53
 
2
 
/
 
2
 
 mouse; Carnero, A.,
and D. Beach, unpublished). To determine the concentra-
tion of MIF that was optimal for colony-forming activity,
we repeated the experiment in the presence of 0–600 ng/ml
rMIF. Elongation of life span was dose dependent, with 150
ng/ml giving the most pronounced effect (Fig. 4 B).
 
Biological Activity of MIF Correlates with Its Ability to Sup-
press p53-responsive Gene Expression in Extending Life Span of
Primary MEFs.
 
Since MIF treatment does not completely
negate p53-mediated gene expression, we sought to test
whether the ability of MIF to induce a p53-related biologi-
cal activity correlated with the relative suppression of p53-
mediated gene expression. Primary MEFs were infected
Figure 3. MIF treatment overcomes p53-dependent apoptosis in fibroblasts and macrophages. (A) Apoptosis in Rat-1/mycER cells. Rat-1/mycER
cells expressing LacZ, MIF, or Bcl2 cDNAs were shifted to media containing 0.1% FBS plus 0.1 mM estradiol to induce apoptosis. After 24 h, cells were
stained with Hoechst 33342 and scored. Cells containing condensed or fragmented DNA cells were scored as apoptotic cells. (B) RAW264.7 macro-
phages were pretreated with varying concentrations of MIF for 24 h, and then treated with 250 mM or 1 mM SNP. Apoptotic nuclei were scored after 2 d.
(C) RAW264.7 macrophages were pretreated with MIF for 16 h, treated with SNP or GSNO for 8 h, and apoptotic cells were scored. 1, 0.5 mM SNP; 2,
1.0 mM SNP; 3, 0.5 mM GSNO; 4, 1.0 mM GSNO; 5, no treatment.
Figure 4. (A) Primary MEFs show extended life span in the presence of
200 ng/ml rMIF. Cells one passage before senescence were plated in the
presence and absence of MIF, and stained after 15 d. Numerous colonies
were formed only in the presence of MIF. (B) Dose dependency of MIF
treatment in inducing extended life span. Primary cells, as in A, were
grown in the presence of varying concentrations of MIF. After 17 d, cells
were crystal violet stained, and washed. Resolubilized crystal violet was
assayed as a measure of cell density. 
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with a virus expressing MIF, an antisense construct directed
against p53 or control virus in passage 2. Infected cells were
selected for drug resistance, cultured, and plated on dupli-
cate plates in passage 5. At the same time, MEFs in passage
5 were plated in the presence or absence of rMIF. 15 d af-
ter plating, one of each duplicate plate was fixed and
stained with crystal violet (Fig. 5 A). Protein extracts were
prepared from the other duplicate plate, and the levels of
p53 and two p53 targets, p21 and Bax (38), were assayed by
Western blot (Fig. 5 B). In each case, the number of colo-
nies observed roughly correlated with the relative suppres-
sion of p53 target gene expression, consistent with the hy-
pothesis that suppression of p53 activity is largely responsible
for this MIF-induced biological activity.
 
Discussion
 
We have demonstrated that MIF treatment was capable
of overcoming p53 activity in three distinct biological as-
says. The ability of a secreted factor to overcome a growth-
inhibitory pathway that has been associated with cellular
mortality and with the response of cells to genotoxic stress
may have an important physiological role. At sites of in-
flammation, MIF is released from T cells and from mac-
rophages (26). High local concentrations of MIF contribute
to T cell activation and enhance the antimicrobial activity
of macrophages (39, 40). When activated, macrophages re-
lease NO and other oxide radicals (41). However, NO can
also induce macrophage apoptosis. Since MIF can partially
negate the p53 response and can protect macrophages from
NO-induced apoptosis, this factor may normally act to
protect macrophages from the destructive machinery they
use to kill invading organisms.
Inflammatory loci are characterized by high rates of cell
death and compensatory proliferation in adjacent cells (42).
At the same time, upregulation of p53 is often observed
(43, 44). Overcoming p53 activity through MIF action
may help to limit the damage response, and therefore to
limit the loss of host cells and to permit local cell prolifera-
tion for tissue repair. After cessation of the inflammatory
state, local levels of MIF decrease, allowing restoration of
the normal damage response.
However, chronic bypass of p53 function by MIF could
contribute to the development of tumors. Loss of p53
function is one of the most common events in human can-
cer. Cells that lack p53 function have enhanced prolifera-
tive potential and display extended life span. In addition,
cells lacking functional p53 are deficient in responding to
chromosome damage (9, 10). During inflammation, release
of highly reactive oxidants by activated phagocytes has
been implicated in the induction of DNA damage in
neighboring cells (20, 21). In the chronic presence of MIF,
cells with attenuated p53 function might continue to pro-
liferate in the presence of DNA damage, and eventually ac-
cumulate multiple oncogenic mutations.
Several chronic inflammatory conditions are strongly as-
sociated with eventual tumor formation (18, 19). For ex-
ample, ulcerative colitis or Crohn’s disease is associated
with the eventual development of bowel cancer, whereas
reflux esophagitis or Barrett’s syndrome has been linked to
the development of esophageal cancer. Schistosomiasis in-
fection predisposes to the development of urinary bladder
cancer, and long term 
 
Helicobacter pylori
 
 infection has been
implicated in the development of gastric cancer. In some
cases of 
 
H. pylori
 
 infection, ablation of the infectious agent
is correlated with reversal of the inflammatory state and
with regression of the associated tumor. This suggests that,
in this model, at least one tumorigenic event requires con-
tinued presence of the inflammatory state, and is reversible
(45). The observation that MIF can interfere with p53
function may provide insight into the mechanisms by
which certain chronic inflammatory conditions predispose
individuals to tumor formation.
 
We thank Lin Xie for the use of LinX retrovirus producer cells, D. Conklin for the use of the A431 cDNA li-
brary in pHygroMarx I, and Michela Armellin for her assistance in scoring apoptotic cells. Many thanks to P.
Otavio de Campos Lima, P. Sun, R. Levinsky, and D. Conklin for helpful discussions and additional reagents.
Figure 5. MIF biological activity corre-
lates with suppression of p53-mediated tar-
get gene expression. Primary MEFs express-
ing MIF (vMIF), an antisense directed
against p53 (p53as), control vector (vector),
or treated with rMIF were plated in passage
5. 15 d after plating cells were (A) fixed and
stained with crystal violet or (B) lysed, and
extracts were probed for p53, Bax, or p21
expression by Western blot. 
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